Detalles de la búsqueda
1.
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies.
Lancet
; 396(10266): 1885-1894, 2020 12 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33308471
2.
Mechanistic Modeling of the Interplay Between Host Immune System, IL-7 and UCART19 Allogeneic CAR-T Cells in Adult B-cell Acute Lymphoblastic Leukemia.
Cancer Res Commun
; 2(11): 1532-1544, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36970053
3.
Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia.
Cancer Res Commun
; 2(11): 1520-1531, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36970059
4.
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.
Lancet Haematol
; 9(11): e833-e843, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36228643
5.
Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma.
Leukemia
; 35(12): 3581-3584, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34145373
Resultados
1 -
5
de 5
1
Próxima >
>>